1 citations
,
January 2017 in “International journal of trichology” Diphenylcyclopropenone (DPCP) effectively treated both alopecia areata and verruca vulgaris.
2 citations
,
June 2016 in “Journal of Medical Science And clinical Research” Barever Natural Hair Inhibitor can help reduce unwanted body hair growth long-term when used with waxing or hair removal cream.
January 2008 in “Journal of Medicinal Chemistry” Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
December 2024 in “Journal of the European Academy of Dermatology and Venereology” Bimatoprost shows promise for treating vitiligo, especially when combined with other therapies.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
February 2010 in “Journal of The American Academy of Dermatology” NB-002 is a promising new topical treatment for fungal nail infections, showing better results than a non-medicated option.
Baricitinib works better than methotrexate for severe alopecia areata.
8 citations
,
April 1990 in “Hormone and Metabolic Research” The medication combination did not affect glucose tolerance but increased some cholesterol levels due to its estrogen component.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
January 2021 in “International Journal of Advanced Research in Medicine” Propranolol, flunarizine, and divalproex sodium are equally effective for preventing migraines, but have different side effects.
February 2024 in “Indian Journal of Chemistry” Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.
February 2023 in “Clinical Toxicology” 20 citations
,
August 2023 in “Saudi Pharmaceutical Journal” Niosomes can effectively deliver cetirizine topically for treating alopecia.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
July 1996 in “Clinical and Experimental Dermatology” Putting calcipotriol ointment on the skin once doesn't change calcium levels in the body right away.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” September 2025 in “Value in Health” 2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
10 citations
,
April 2020 in “Dermatology and therapy” Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.
January 2025 in “International Journal of Pharmacology” Both steroids, especially cyproterone acetate, harm quail's vital organs.
April 2019 in “Journal of the Endocrine Society” An over-the-counter vitamin/mineral supplement improved hair loss and blood sugar control in a woman with non-classic 11-hydroxylase deficiency.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
21 citations
,
April 2011 in “Epilepsia” The drug combination significantly reduced epileptic drop attacks in patients.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.